Evolocumab como tratamiento de la dislipemia secundaria a lorlatinib / Evolocumab as treatment in lorlatinib-related hyperlipidemia
Clín. investig. arterioscler. (Ed. impr.)
; 35(2): 88-90, Mar-Abr. 2023. tab
Article
in Es
| IBECS
| ID: ibc-219215
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
RESUMEN
Los anticuerpos monoclonales anti-PCSK9 han demostrado reducción de eventos cardiovasculares en pacientes con enfermedad vascular ateroesclerótica1. Sin embargo, no está descrito su uso en el tratamiento de la dislipemia secundaria a lorlatinib, un inhibidor competitivo de la quinasa del linfoma anaplásico de tercera generación, indicado en cáncer de pulmón no microcítico avanzado ALK+.(AU)
ABSTRACT
Anti-PCSK9 monoclonal antibodies have reduced the risk of cardiovascular events in patients with atheroesclerosis cardiovascular disease. However, its use has not been described in hyperlipidemia associated with lorlatinib, a third-generation ALK tyrosin kinasa inhibitor approved as treatment for ALK-positive non-small cell lung cancer.(AU)
Key words
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Physical Examination
/
Atherosclerosis
/
Hyperlipidemias
/
Inpatients
/
Antibodies, Monoclonal
Limits:
Female
/
Humans
Language:
Es
Journal:
Clín. investig. arterioscler. (Ed. impr.)
Year:
2023
Document type:
Article